Catalyst
Slingshot members are tracking this event:
FDA approves new dosage strength of Teva's (TEVA) buprenorphine and naloxone sublingual film as maintenance treatment for opioid dependence
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TEVA |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Buprenorphine, Naloxone, Sublingual Tablets, Opioid Addiction
